loading...| Preferred Name |
peginterferon alfa-2b |
|
| Synonyms |
PEG interferon alfa-2b |
|
| Definitions |
A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1845" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1845" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000043407 |
|
| altLabel |
PEG interferon alfa-2b polyethylene glycol IFN-A2b Sylatron PEG-IFN-a 2b pegylated interferon alfa-2b SCH 54031 PEG-Interferon Alfa-2B PEG-IFN alfa-2b polyethylene glycol interferon alfa-2b PEG-Intron PEG-IFNA2b |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000445423 http://purl.bioontology.org/ontology/PDQ/CDR0000269112 http://purl.bioontology.org/ontology/PDQ/CDR0000285641 |
|
| cui |
C1527737 C0796545 C1527096 C3153371 |
|
| Date last modified |
2013-05-06 |
|
| definition |
A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1845" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1845" NCI Thesaurus) |
|
| Legacy PDQ ID |
7966 |
|
| LT |
TRD |
|
| NCI ID |
C1845 |
|
| notation |
CDR0000043407 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
peginterferon alfa-2b |
|
| tui |
T116 T129 T121 |